La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

BeyondSpring Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di BeyondSpring.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili	30.3%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Sep 07

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

Aug 01

BeyondSpring EPS misses by $0.04

Jun 16

BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia

Jun 07

FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%

Jun 01

BeyondSpring EPS misses by $0.17

Apr 30

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

Dec 22

BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution

Dec 15

BeyondSpring slides 9% on public offering pricing at $10.0/share

Nov 19

BeyondSpring under pressure on shares offering

Nov 17

BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial

Nov 16

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché BeyondSpring non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:BYSI - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2023	2	-21	-17	-16	N/A
9/30/2023	2	-24	N/A	N/A	N/A
6/30/2023	2	-28	N/A	N/A	N/A
3/31/2023	1	-30	N/A	N/A	N/A
12/31/2022	1	-33	-28	-28	N/A
9/30/2022	1	-35	N/A	N/A	N/A
6/30/2022	1	-46	N/A	N/A	N/A
3/31/2022	1	-56	N/A	N/A	N/A
12/31/2021	1	-64	-50	-47	N/A
9/30/2021	1	-72	-37	-37	N/A
6/30/2021	1	-68	-52	-52	N/A
3/31/2021	1	-62	-52	-52	N/A
12/31/2020	0	-61	-44	-44	N/A
9/30/2020	N/A	-57	-49	-49	N/A
6/30/2020	N/A	-52	-60	-60	N/A
3/31/2020	N/A	-47	-54	-54	N/A
12/31/2019	N/A	-38	-48	-48	N/A
9/30/2019	N/A	-38	-44	-44	N/A
6/30/2019	N/A	-44	-31	-31	N/A
3/31/2019	N/A	-49	-36	-36	N/A
12/31/2018	N/A	-55	-40	-40	N/A
9/30/2018	N/A	-56	-42	-42	N/A
6/30/2018	N/A	-57	-40	-40	N/A
3/31/2018	N/A	-58	-33	-32	N/A
12/31/2017	N/A	-92	-29	-29	N/A
9/30/2017	N/A	-80	N/A	-24	N/A
6/30/2017	N/A	-67	N/A	-19	N/A
3/31/2017	N/A	-58	N/A	-17	N/A
12/31/2016	N/A	-12	N/A	-14	N/A
9/30/2016	N/A	-10	N/A	-11	N/A
6/30/2016	N/A	-9	N/A	-9	N/A
3/31/2016	N/A	-8	N/A	-7	N/A
12/31/2015	N/A	-8	N/A	-7	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista BYSI è superiore al tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di BYSI cresceranno più velocemente del mercato US

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di BYSI cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di BYSI cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di BYSI cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di BYSI è previsto essere elevato tra 3 anni

BeyondSpring Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased to US$2.30

Price target decreased to US$6.10

Consensus forecasts updated

Price target increased to US$13.67

Consensus revenue estimates fall by 90%

Consensus forecasts updated

Recent updates

New minor risk - Market cap size

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Rule

First half 2023 earnings released: US$0.33 loss per share (vs US$0.47 loss in 1H 2022)

New major risk - Revenue and earnings growth

BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin’s Immunomodulating Activity

New minor risk - Financial data availability

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

BeyondSpring Inc. Announces Retirement of Yanbin Xie as Board of Director

Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

BeyondSpring Inc. Announces New Data from Phase 1 Investigator Initiated Study Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

BeyondSpring Inc. Announces the Resignation of Christine Ying Zhao from the Board of Directors, Effective January 1, 2023

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Price target decreased to US$2.30

BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

BeyondSpring Inc. Announces Board Appointments

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell 2000 Dynamic Index

BeyondSpring Inc. Announces Executive Resignations, with Effect from June 9, 2022

BeyondSpring Inc. Announces Resignation of Gordon L. Schooley as Chief Regulatory Officer

Price target decreased to US$6.10

Elizabeth Czerepak Resigns as Executive Vice President of BeyondSpring Inc

Consensus forecasts updated

Price target increased to US$13.67

BeyondSpring Inc. to Report Q4, 2021 Results on Apr 14, 2022

BeyondSpring, Beyond Salvage

BeyondSpring Pharmaceuticals Announces Organizational Streamlining

Consensus revenue estimates fall by 90%

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in Prevention of Chemotherapy-Induced Neutropenia at 63rd ASH Annual Meeting and Exposition

Consensus forecasts updated

BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)

No longer forecast to breakeven

Circling Back On BeyondSpring

Price target decreased to US$58.60

Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Price target increased to US$67.25

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

Consensus forecasts updated

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell Microcap Value Index

Consensus forecasts updated

BeyondSpring EPS misses by $0.04

BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting

BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia

BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

BeyondSpring Inc. Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia

FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%

BeyondSpring EPS misses by $0.17

BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting

Chief Scientific Officer has left the company

BeyondSpring Inc. Announces Management Changes

Price target lowered to US$36.00

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors

BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution

BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium

BeyondSpring Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

BeyondSpring slides 9% on public offering pricing at $10.0/share

BeyondSpring Announces Positive Topline Results from Its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia

BeyondSpring under pressure on shares offering

BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial

New 90-day high: US$16.02

BeyondSpring Forms Partnership Advisory Committee

New 90-day high: US$15.36

BeyondSpring Inc. Announces JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy

BeyondSpring Inc. Announces New Clinical Data on Late-Stage Asset, Plinabulin

BeyondSpring Inc. Appoints Elizabeth Czerepak as Chief Financial Officer